Company Announcement

CLINUVEL

ASX: CUV
Nasdaq International Designation: CLVLY
XETRA-DAX: UR9

CLINUVEL DECLARES FINAL DIVIDEND

Directors declare dividend upon achievement of third consecutive annual profit

- CLINUVEL Group to declare second consecutive annual unfranked dividend of A$0.025 per ordinary share following financial results for the year ending 30 June 2019
- Record date: 05 September 2019
- Ex-Dividend date: 17 September 2019
- Payment date: 19 September 2019

Melbourne, Australia, 28 August 2019

CLINUVEL PHARMACEUTICALS LTD **(ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY)** is pleased to announce that it will issue a dividend for the financial year ended 30 June 2019. This is the second final dividend in its corporate history.

Subject to the Company maintaining sufficient reserves, the Board of Directors have agreed to issue an unfranked dividend of A$0.025 per ordinary share for the financial year ended 30 June 2019. The dividend record date is set at 5 September 2019 and the payment date is set at 19 September 2019. The issuance of the dividend is a 25% increase compared to the maiden unfranked dividend of A$0.02 declared for the financial year ended 30 June 2018, and which was paid to shareholders on 8 October 2018.

The Board of Directors express their appreciation of the continued long-term support of investors who enabled the development of CLINUVEL's drug SCENESSE® (afamelanotide 16mg) since the Company listed on the ASX in 2001.[1] Shareholders have now witnessed the third consecutive full-year profit driven by its commercial operations in Europe which is delivering accretive value to shareholders in terms of value of investment, return on equity, earnings per share and now, for the second consecutive year, dividend.

Dividends are available to Australian and overseas registered shareholders, including holders of CLINUVEL's Level 1, American Depository Receipts.

Prior to the record date, shareholders are encouraged to confirm their personal shareholder information, including payment election information, with the share registrar.

COMMENTARY

"An Australian pharmaceutical company having started in research and now having achieved three consecutive years of profitability and a record profit in the 2019 financial year, we consider it reasonable to declare a second consecutive annual distribution of earnings to augment the overall return to shareholders on their investment in the Company," CLINUVEL's Non-Executive Director and Chair of the Audit & Risk Committee, Mrs Brenda Shanahan said.

"Without our investors, we would not have been able to develop SCENESSE® to provide treatment to patients with a rare genetic metabolic disorder, erythropoietic protoporphyria (EPP) who for the first time have enjoyed the freedom to live a full life. The Board appreciates the ongoing support of our shareholders and wish to acknowledge

their contribution to the CLINUVEL Group through this second dividend in the Company's history." Mrs Shanahan said.

- End -

[1] SCENESSE® (afamelanotide16mg) is approved in Europe as an orphan medicinal product for the prevention of phototoxicity in adult patients with EPP. Information on the product can be found on CLINUVEL's website at www.clinuvel.com.

About CLINUVEL PHARMACEUTICALS LIMITED
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL's lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Switzerland, the US and Singapore, with the UK acting as the EU distribution centre. For more information go to http://www.clinuvel.com.

SCENESSE® is a registered trademark of CLINUVEL PHARMACEUTICALS LTD.

Head of Investor Relations
Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor enquiries
https://www.clinuvel.com/investors/contact-us

Forward-Looking Statements
This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg); our ability to achieve expected safety and efficacy results through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; any failure to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2019 Preliminary Financial Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on the forecasts and estimates is available on request. Past performance is not an indicator of future performance.

www.clinuvel.com
Level 11 T +61 3 9660 4900
535 Bourke Street F +61 3 9660 4999
Melbourne
Victoria, Australia, 3000, 28 August 2019